Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Pink who wrote (5695)	8/25/2000 8:50:20 PM
From: Peter V	Read Replies (1) \| Respond to of 5736

Slow trading day today, only 10 times normal volume. I guess the following PR didn't help much, got down to under 1 1/2. Sorry I wasn't paying attention, I was busy watching my EMLX bounce around like a pinball. Friday August 25, 8:16 am Eastern Time Press Release SOURCE: Chromatics Color Sciences International, Inc. Chromatics Color Sciences International, Inc. Responds to Market Activity NEW YORK, Aug. 25 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI - news) announced today that the recent large volume of trading and the decline in the Company's stock price was not due to any adverse event in the Company, its operations or business affairs. Brian Fitzpatrick, the CEO of CCSI, stated, ``Following the recent transition in management announced earlier this month, I will be holding an Investors' Conference Call after Labor Day to articulate the strategic directions developed by the new management team relative to the Company's next phase of expanding commercial market applications.'' Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties in this field. The Company has received clearance from the Food and Drug Administration (FDA) for the commercial use of its medical device for the non-invasive monitoring of bilirubinemia in newborn infants by healthcare professionals in hospitals, clinics, pediatrician offices and the home environment. The Company believes its technologies and intellectual properties may also have medical applications in the detection and monitoring of other chromogenic diseases which the Company defines as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. Medical applications, in addition to the non-invasive monitoring of bilirubinemia in newborns, will require additional clinical trials and FDA clearances for commercial use.